Results 21 to 30 of about 6,560 (205)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection

Journal of Family Medicine and Primary Care, 2022
Molnupiravir is a novel antiviral agent for coronavirus disease 2019 (COVID-19) treatment. Warfarin is an oral anticoagulation agent with difficult management due to drug interactions.
Hikari Mizutani, Tetsuro Koide, Takashi Omura, Kumiko Ito   +3 more
doaj   +1 more source

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Frontiers in Pharmacology, 2022
Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective ...
Rongrong Zou, Ling Peng, Dan Shu, Lei Zhao, Jianfeng Lan, Guoyu Tan, Jinghan Peng, Xiangyi Yang, Miaona Liu, Chenhui Zhang, Jing Yuan, Huxiang Wang, Song Li, Hongzhou Lu, Wu Zhong, Yingxia Liu   +15 more
doaj   +1 more source

Molnupiravir for treating COVID-19 [PDF]

Cochrane Database of Systematic Reviews, 2022
Objectives\ud This is a protocol for a Cochrane Review (intervention). The objectives are as follows:\ud \ud To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.
Ochodo, Eleanor, Owino, Eddy, Nyagol, Bruce, Fox, Tilly, McCaul, Michael, Kredo, Tamara, Cohen, Karen, Rupali, Priscilla   +7 more
openaire   +1 more source

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

Infectious Diseases and Therapy, 2023
Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Masahiro Kimata, Asuka Watanabe, Yukiko Yanagida, Daisuke Kinoshita, Shinichiroh Maekawa   +4 more
doaj   +1 more source

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat

Communications Medicine, 2023
Background The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Ling Yang, Tung-Yi Lin, Muh-Hwa Yang, Tung-Hu Tsai   +6 more
doaj   +1 more source

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial

Frontiers in Pharmacology, 2023
Introduction: Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir.Methods:
Yayun Liu, Shiyong Fan, Aijing Xu, Lingling Ge, Xinyu Wang, Xu Dong, Mingxiao Xu, Wenhan Fan, Wu Zhong, Xuesong Liang   +9 more
doaj   +1 more source

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrierResearch in context

EBioMedicine, 2023
Summary: Background: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Tung-Yi Lin, Muh-Hwa Yang, Jeffrey W. Dalley, Tung-Hu Tsai   +6 more
doaj   +1 more source

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19

Viruses, 2023
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in animal models of COVID-19, prompting clinical trials, in which initial results indicated a significant effect against the disease.
Henrik Berg Rasmussen, Peter Riis Hansen
doaj   +1 more source

Towards a Practical, Non-enzymatic Process for Molnupiravir from Cytidine

, 2021
A scalable four step synthesis of molnupiravir from cytidine is described herein. The attractiveness of this approach is its fully chemical nature involving inexpensive reagents and more environmentally friendly solvents such as water, isopropanol ...
Gopal, Sirasani, Rodger W., Stringham, Daniel W., Cook, Rudy, Krack, B. Frank, Gupton, Ajay, Yadaw, Justina, Burns, David, Snead, Appasaheb L., Kadam, Timothy F., Jamison, Corshai, Williams, Chris, Senanayake, Vijayagopal, Gopalsamuthiram, Jeffrey, Noble, Sarabindu, Roy, Saeed, Ahmad   +15 more
core   +1 more source

New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method [PDF]

Cellular, Molecular and Biomedical Reports, 2023
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form.
Gandu Sravanthi, Kumara Gandla, Lalitha Repudi   +2 more
doaj   +1 more source